Research graph
References from Synthesis, characterisation, and in vitro assessment of hyaluronic acid-coated solid lipid nanoparticles entrapping dexamethasone palmitate designed for intra-articular administration. Local targets link to admitted publications; unresolved targets remain external evidence.
Developments in the scientific understanding of OA
10.1186/ar2655 · 2009 · External reference
Microfluidics for development of lipid nanoparticles: paving the way for nucleic acids to the clinic
10.1021/acsabm.1c00732 · 2021 · External reference
Current evidence for OA treatments
10.1177/1759720x09359889 · 2010 · External reference
Preparation of cetyl palmitate-based PEGylated solid lipid nanoparticles by microfluidic technique
10.1016/j.actbio.2020.12.024 · 2021 · External reference
Preparation and characterization of novel nanostructured lipid carriers (NLC) and solid lipid nanoparticles (SLN) containing coenzyme Q10 as potent antioxidants and antityrosinase agents
10.1016/j.heliyon.2024.e31429 · 2024 · External reference
The use of solid lipid nanoparticles for sustained drug release
10.4155/tde.15.23 · 2015 · External reference
An effective approach in OA: diacerein-loaded solid lipid nanoparticles, preparation and evaluation for targeted therapy
10.1016/j.jddst.2025.106856 · 2025 · External reference
Intraarticular injections (corticosteroid, hyaluronic acid, platelet rich plasma) for the knee OA
10.5312/wjo.v5.i3.351 · 2014 · External reference
High payload dexamethasone palmitate-loaded solid lipid nanoparticles for enhanced anti-inflammatory effects in acute skin inflammation model
10.1007/s40005-024-00674-x · 2024 · External reference
Intra-articular hyaluronic acid in the treatment of knee OA: a Canadian evidence-based perspective
10.1177/1759720x17729641 · 2017 · External reference
Intra-articular targeting of nanomaterials for the treatment of OA
10.1016/j.actbio.2019.03.010 · 2019 · External reference
Intra-Articular drug delivery for OA treatment
10.3390/pharmaceutics13122166 · 2021 · External reference
Trends and cross-country inequalities in the global burden of OA, 1990-2019: a population-based study
10.1016/j.arr.2024.102382 · 2024 · External reference
Hyaluronan-loaded liposomal dexamethasone–diclofenac nanoparticles for local OA treatment
10.3390/ijms22020665 · 2021 · External reference
Solid lipid nanoparticles loaded with dexamethasone palmitate for pulmonary inflammation treatment by nebulization approach
10.3390/pharmaceutics16070878 · 2024 · External reference
Mechanisms and pharmaceutical action of lipid nanoformulation of natural bioactive compounds as efficient delivery systems in the therapy of OA
10.3390/pharmaceutics13081108 · 2021 · External reference
Global, regional prevalence, incidence and risk factors of knee OA in population-based studies
10.1016/j.eclinm.2020.100587 · 2020 · External reference
A brief review on solid lipid nanoparticles: part and parcel of contemporary drug delivery systems
10.1039/d0ra03491f · 2020 · External reference
An introduction to biotechnology: science, technology, and medical applications
2014 · External reference
New insights into the pro-inflammatory and osteoclastogenic profile of circulating monocytes in OA patients
10.3390/ijms25031710 · 2024 · External reference
Tristearin bilayers: structure of the aqueous interface and stability in the presence of surfactants
10.1039/c5ra09192f · 2015 · External reference
OA in 2020 and beyond: a Lancet Commission
10.1016/s0140-6736(20)32230-3 · 2020 · External reference
Influence of process variables on particle size of solid lipid nanoparticles
2009 · External reference
PEGylated solid lipid nanoparticles: design, methotrexate loading and biological evaluation in animal models
10.1039/c5md00104h · 2015 · External reference
Self-assembled hyaluronic acid nanoparticles for OA treatment
10.1016/j.biomaterials.2021.120967 · 2021 · External reference
Review on the scale-up methods for the preparation of solid lipid nanoparticles
10.3390/pharmaceutics14091886 · 2022 · External reference
Reproducible synthesis of biocompatible albumin nanoparticles designed for intra-articular administration of celecoxib to treat OA
10.1021/acsami.4c02243 · 2024 · External reference
2019 American College of Rheumatology/Arthritis Foundation Guideline for the management of OA of the hand, hip, and knee
10.1002/acr.24131 · 2020 · External reference
Hyaluronic acid-coated solid lipid nanoparticles to overcome drug-resistance in tumor cells
10.1016/j.jddst.2019.01.042 · 2019 · External reference
Nanoparticle–Cartilage interaction: pathology-based intra-articular drug delivery for OA therapy
10.1007/s40820-021-00670-y · 2021 · External reference
Dexamethasone palmitate nanoparticles: an efficient treatment for rheumatoid arthritis
10.1016/j.jconrel.2019.01.015 · 2019 · External reference
Solid lipid nanoparticles as drug delivery systems
10.1358/mf.2005.27.2.876286 · 2005 · External reference
Solid lipid nanoparticles as intracellular drug transporters: an investigation of the uptake mechanism and pathway
10.1016/j.ijpharm.2012.03.032 · 2012 · External reference
Long-term adverse effects of paracetamol - a review
10.1111/bcp.13656 · 2018 · External reference
Importance of solid lipid nanoparticles (SLN) in various administration routes and future perspectives
10.2147/ijn.s2.3.289 · 2022 · External reference
Hyaluronic acid-coated chitosan nanoparticles as an active targeted carrier of alpha Mangostin for breast cancer cells
10.3390/polym15041025 · 2023 · External reference
Solid lipid nanoparticles: emerging colloidal nano drug delivery systems
10.3390/pharmaceutics10040191 · 2018 · External reference
Hyaluronic acid-coated magnetic solid lipid nanoparticles for cancer-targeted delivery of gemcitabine and imaging agent
10.1016/j.carpta.2025.100946 · 2025 · External reference
Emerging intra-articular drug delivery systems for the temporomandibular joint
10.1016/j.ymeth.2008.09.001 · 2009 · External reference
Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations
10.1016/s0169-409x(02)00118-7 · 2022 · External reference
Mechanisms of OA (OA) pain
10.1007/s11914-018-0477-1 · 2018 · External reference
Triamcinolone acetonide extended-release: a review in OA pain of the knee
10.1007/s40265-019-01083-3 · 2019 · External reference
Delivery of chlorambucil to the brain using surface modified solid lipid nanoparticles
10.1021/acsabm.4c00326 · 2024 · External reference
Surface-engineered hyaluronic acid-coated lyotropic liquid crystalline nanoparticles for CD44-targeting of 3-Acetyl-11-keto-beta-boswellic acid in rheumatoid arthritis treatment
10.1186/s12951-025-03846-5 · 2025 · External reference
A Study of hyaluronic acid's theoretical reactivity and of magnetic nanoparticles capped with hyaluronic acid
10.3390/ma17061229 · 2024 · External reference
Manufacturing considerations for the development of lipid nanoparticles using microfluidics
10.3390/pharmaceutics12111095 · 2020 · External reference
An intra-articular salmon calcitonin-based nanocomplex reduces experimental inflammatory arthritis
10.1016/j.jconrel.2013.01.027 · 2013 · External reference
Hyaluronic acid-based nanosystems for CD44 mediated anti-inflammatory and antinociceptive activity
10.3390/ijms24087286 · 2023 · External reference
Commentary: new perspectives on protein aggregation during biopharmaceutical development
10.1016/j.ijpharm.2018.09.049 · 2018 · External reference
Microfluidic formulation of nanoparticles for biomedical applications
10.1016/j.biomaterials.2021.120826 · 2021 · External reference
Intra-articular delivery of a nanocomplex comprising salmon calcitonin, hyaluronic acid, and chitosan using an equine model of joint inflammation
10.1007/s13346-018-0557-x · 2018 · External reference
Mechanisms of glucocorticoid receptor signaling during inflammation
10.1016/j.mad.2004.06.010 · 2004 · External reference
Safety and efficacy of repeat administration of triamcinolone acetonide extended-release in OA of the knee: a phase 3b, open-label Study
10.1007/s40744-019-0140-z · 2019 · External reference
Global, regional, and national burden of OA, 1990–2020 and projections to 2050: a systematic analysis for the global Burden of Disease Study 2021
10.1016/s2665-9913(23)00163-7 · 2023 · External reference
Lipid nanoparticles─from liposomes to mRNA vaccine delivery, a landscape of research diversity and advancement
10.1021/acsnano.1c04996 · 2021 · External reference
Emerging nanoparticle platforms to improve the administration of glucocorticoids
10.1016/j.jconrel.2023.04.039 · 2023 · External reference
Lipopolysaccharide-induced inflammation in monocytes/macrophages is blocked by liposomal delivery of G(i)-protein inhibitor
10.2147/ijn.s150918 · 2018 · External reference
OA year in review 2020: biology
10.1016/j.joca.2020.10.006 · 2021 · External reference
Use of microfluidics to prepare lipid-based nanocarriers
10.3390/pharmaceutics15041053 · 2023 · External reference
Hyaluronic acid decorated pluronic P85 solid lipid nanoparticles as a potential carrier to overcome multidrug resistance in cervical and breast cancer
10.1016/j.biopha.2016.12.041 · 2017 · External reference
Effectiveness of intra-articular therapies in OA: a literature review
10.1177/1759720x17712695 · 2017 · External reference
Revisiting prostaglandin E2: a promising therapeutic target for OA
10.1016/j.clim.2024.109904 · 2024 · External reference
Hyaluronic acid coated acid-sensitive nanoparticles for targeted therapy of adjuvant-induced arthritis in rats
10.3390/molecules24010146 · 2019 · External reference
Hyaluronic acid coated teriflunomide (A771726) loaded lipid carriers for the oral management of rheumatoid arthritis
10.1016/j.ijpharm.2022.121939 · 2022 · External reference
Microfluidics for nano-drug delivery systems: from fundamentals to industrialization
10.1016/j.apsb.2023.01.018 · 2023 · External reference
Hyaluronic acid-coated MTX-PEI nanoparticles for targeted rheumatoid arthritis therapy
10.3390/cryst11040321 · 2021 · External reference
Targeted delivery of hyaluronic acid-coated solid lipid nanoparticles for rheumatoid arthritis therapy
10.1080/10717544.2018.1447050 · 2018 · External reference
